Escalating drug prices are at the centre of the raging debates on the seemingly uncon-trollable costs of providing healthcare. Making available generic substitutes for the more expensive, patented drugs is a core element of many healthcare cost-reduction plans. In the United States, the Orange Book serves to promote expedited entry of generic drugs into the marketplace while simultaneously protecting the interest of drug patent owners.
